Epithalon | CAS:307297-39-8

We serve Epithalon CAS:307297-39-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Epithalon

Chemical Name:Epithalon
CAS.NO:307297-39-8
Synonyms:Epithalon
L-Alanyl-L-α-glutamyl-L-α-aspartylglycine
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 959.8±65.0 °C at 760 mmHg
Molecular Formula C14H22N4O9
Molecular Weight 390.346
Flash Point 534.3±34.3 °C
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.559
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Epitalon can Life extension by elongation of telomeres and telomerase activation, they maintain the body strong and healthy.Telomerase (a.k.a. telomere terminal transferase) is the enzyme capable to elongate telomeres in human bodies, protecting the DNA from the damage caused by aging.
Epitalon and the anti-aging properties. he structure of Epitalon is: Ala-Glu-Asp-Gly. Epitalon decreases the age related changes in the immune and the neuroendocrine systems, reducing the incidence of chronic diseases and infections.



Contact us for information like Epithalon chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,L-Alanyl-L-α-glutamyl-L-α-aspartylglycine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,L-Alanyl-L-α-glutamyl-L-α-aspartylglycine Use and application,L-Alanyl-L-α-glutamyl-L-α-aspartylglycine technical grade,usp/ep/jp grade.


Related News: It’s the first confirmed Wuhan coronavirus death from outside of mainland China, and brings the total toll to 305.2-fluoroadenine manufacturer Subsequently, the company launched the drug under the brand names ‘Remo’ and ‘Remozen’.4-Bromocumene supplier “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.1-IODO-3-FLUOROPROPANE vendor “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.The best you can do is take medicines and treatments for specific symptoms.